Highlights: Corticosteroid therapy often induces hyperglycemia , even in patients without pre-existing type 2 diabetes mellitus (T2DM), due to insulin resistance and islet-cell dysfunction. 1 Incretin-based therapies may preserve glucose tolerance and pancreatic islet-cell function. 2 The dipeptidyl peptidase-4 (DPP-4) inhibitors action on stimulation of insulin secretion and inhibition of glucagon secretion , state them as potentially beneficial for the treatment of glucocorticoid-induced diabetes.
1 This article focuses on DPP-4 inhibitors potential and efficacy as therapeutics for the improvement of steroid-induced hyperglycemia. Steroid-induced glucose intolerance and incretin effects Corticosteroids, such as glucocorticoids are used to suppress inflammation and control cytokine storm and can cause associated complications, such as worsening diabetes, avascular necrosis, and…
